Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering
All of the shares in the offering are being offered by Tenaya. The gross proceeds to Tenaya from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be
Morgan Stanley, Cowen and Piper Sandler are acting as joint book-running managers for the offering. Chardan is acting as lead manager for the offering.
Registration statements relating to the offering have been filed with the
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
About Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from
For more information, please contact: